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Abstract
The management of infections in surgical intensive care unit patients poses specific challenges. Although the
overall approach to the patient is no different from other patients, diagnosis is often problematic. As in other
infections, multidrug resistance is increasingly described, and changes in pharmacokinetics may require different
dosing strategies. Also the need for source control adds a level of complexity to the management of the patient.
Whereas source control was a purely surgical issue before, percutaneous drainage has emerged as an important
alternative. Appropriate timing of source control often remains difficult to determine, but in most severe infections
source control should not be delayed. But also the need for a multidisciplinary approach can make the decision
making difficult. New concepts such as dedicated source control teams may further assist in selecting the most
appropriate treatment strategy and further improve outcome of surgical severe sepsis patients.
Review
Introduction
Severe infections in surgical patients may be the reason
for admission in some, but may also develop during in-
tensive care unit (ICU) stay in others. These infections
are an important burden in modern critical care, in
terms of morbidity, mortality and resource use. In a re-
cent study from China, mortality was high in surgical
ICU (SICU) patients developing severe sepsis (48.7%) [1]
and nursing workload high.
Abdominal infections more in particular, are associ-
ated with a long ICU stay, more shock and acute kidney
injury and a higher mortality compared to other infec-
tions [2,3] and therefore deserve proper attention.
Although there are no standardized definitions of what
constitutes SICU patients, patients admitted after recent
surgery (within the preceding 2-4 weeks, including emer-
gency surgery (a non-scheduled operation within 24 hours
of the onset of symptoms or injury)) are considered surgi-
cal [3,4] and the focus of the current review.
The overall approach to infections in surgical patients is
comparable to other patient categories, with rapid admin-
istration of appropriate antibiotics as one of the most im-
portant elements. The role of source control however
should not be underestimated and is to be considered
more often. To this extent, communication and inter-
action with other specialties such as surgery and interven-
tional radiology is pivotal and preferably these patients
should be managed in a multidisciplinary way. Diagnosis,
both of primary infections or infections where the initial
therapy has failed are particularly challenging but also the
application of other, newer concepts such as antimicrobial
de-escalation may be different.
Rather than listing antibiotic therapy schemes for com-
monly encountered infections, we will review specific as-
pects of the treatment of infections in SICU patients.
Epidemiology of infections in surgical ICU patients
SICU patients apparently are at the highest risk to be di-
agnosed with an infection, presumably because the infec-
tion itself was the cause for admission to the ICU more
often; as an example, in the Sepsis Occurrence in Acutely
ill Patients (SOAP) study, 89% of the abdominal infections
were non-ICU acquired [3], the highest percentage of fre-
quently encountered infections studied.
In the European Prevalence of Infections in Intensive
Care (EPIC)-II study, about two thirds of the infected pa-
tients were considered surgical patients (emergency sur-
gery mostly, but also trauma and elective surgery) [4].
Obviously not all of these patients had typical surgical
sources of infection.
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In a large study from China, abdominal infections
accounted for 72 percent of the infections in SICU pa-
tients diagnosed with severe sepsis, with acute pancreatitis
and gastrointestinal perforation as the leading sources of
infection [1]. Notably more than half of the cases had in-
fections in multiple locations.
As the sources of infections are different compared to
general ICU patients, these SICU infections also have a
distinct microbiology pattern. Cheng et al. found that 43.7
percent of infections were polymicrobial, with a compar-
able contribution of Gram-positive and Gram-negative
bacteria [1]. Fungi were also present in a considerable
number of infections in this multicenter study (28.3%). In
the SOAP study, Gram-positive bacteria (mainly Strepto-
coccus D) and Escherichia coli were more frequently iso-
lated in surgical patients [3].
Diagnosing infections in surgical ICU patients
Typically, SICU patients with infectious complications are
either admitted with an infection (mostly postoperative)
or they develop it during their admission for another pri-
mary diagnosis. Both categories pose specific problems in
terms of timely diagnosis to allow early therapy.
Diagnostics of infections in SICU patients admitted for
non-infectious reasons can be puzzling as the tools we tend
to rely on are unreliable in many situations. SIRS criteria are
non-specific and frequently a reflection of postoperative
inflammation, trauma, burns or any other inflammatory
process. Similarly, conventional biomarkers of inflammation
are often useless to diagnose infections immediately after
another event. Also signs of impending organ dysfunction
in a setting of severe sepsis, such as hypotension or oliguria,
may be the result of other postoperative complications such
as bleeding, fluid losses or under-resuscitation.
In patients admitted after surgical (or interventional)
treatment, the diagnosis of recurrent infection due to
failed source control is a problem that poses particular
challenges. In a prospective multicenter study, Van Ruler
et al. found that – contrary to what one may think – the
extent of peritonitis, the source of the infection, the type
of contamination or operative variables such as the pres-
ence of an anastomosis, were not associated with recur-
rent infection. Adding postoperative symptoms such as
fever and parameters of organ dysfunction to the multi-
variate model, could identify patients requiring additional
source control measures [5]. Most commonly used scoring
systems perform poorly in this setting, only acute organ
dysfunction scores such as the SOFA score were some-
what useful [6], although the AUROC was only 0.61 for
the best discriminative score. Biomarkers may be superior
in identifying patients without surgical source control; in a
small study Novotny et al. found that a ratio of PCT on
day 2 to PCT on day 1 of 1.03 or higher could discrimin-
ate failed from effective source control [7].
Clinical suspicion is probably best to track failed source
control early; when available, PCT can be used for con-
firmation, but further work up remains necessary. Bedside
ultrasound and abdominal CT scan represent the best
tools; ultrasound has the advantage that it is readily avail-
able in most units and does not require transportation to
the CT lounge and contrast administration. Both imaging
techniques can be complemented by fine needle aspiration
of suspected collections, or percutaneous drainage (PCD)
in case of collections amenable to catheter treatment. In
most situations, PCD is preferable over open surgery to
confirm the diagnosis.
Antibiotic therapy
Similar to the general ICU population, the empirical
antibiotic scheme should cover the probable pathogen
(s). This knowledge needs to be supplemented with local
ecology data to determine the most appropriate empirical
antimicrobial regimen. In abdominal infections inadequate
antimicrobial therapy is associated with an increase in
mortality rates in several studies [8-10].
As in other infections involvement of multidrug resist-
ant (MDR) pathogens is a major concern. Seguin et al.
found this risk to be particularly elevated in patients who
were hospitalized for 5 days or longer and after previous
exposure to antibiotics; when both criteria were present
MDR was present in 38% of the infections compared to
2% when both were absent [11]. Swenson et al. reported
an association between health-care exposure; e.g. current
ICU admission, hospitalization for more than one week,
but also including hospitalization within one month prior
to the infection, residence in a nursing home or rehabilita-
tion facility, and the occurrence of MDR pathogens [12].
When selecting empirical and directed antimicrobial
therapy in the setting of surgical infections, we have to take
some limitations of the microbiology diagnostic techniques
into account. Abdominal infections are typically polymi-
crobial with both Gram-positive and Gram-negative, aer-
obe and anaerobe bacteria contributing in most patients.
Depending on the techniques used, up to 10-15 microor-
ganisms can be found in cultures from intra-abdominal
infections, but pathogenicity may be difficult to assess. An-
aerobe microbes are difficult to culture and even if these
are not reported by the microbiology lab, these should be
covered by the antibiotic therapy [13]. This is equally rele-
vant in necrotizing skin and soft tissue infections where an
important part of infections are polymicrobial [14].
De-escalation can be a challenging issue in SICU pa-
tients. As discussed above, infections are often present in
multiple sites, and are often polymicrobial, limiting the
possibilities of de-escalation in these patients. This was
found in an earlier study from our center where abdom-
inal infection and the lack of conclusive microbiology were
important obstacles to de-escalation [15].
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In recent years the changes in the pharmacokinetics in
critically ill patients has received increased interest [16]. Al-
though these changes are not limited to surgical patients,
again specific issues should be considered in SICU infected
patients as it may impact outcome [17]. One of the main
determinants of decreased exposure to antimicrobial ther-
apy is increased elimination of the antibiotic (mostly beta-
lactam antibiotics) through a phenomenon of augmented
renal clearance. Augmented renal clearance is a frequent
finding in critically ill patients and certain categories of
SICU patients such as trauma and burn patients [18]. In
specific patient populations e.g. following abdominal sur-
gery, increased fluid losses though abdominal drains may
further decrease antibiotic concentrations [19]. Different
dosing strategies such as extended or continuous infusion
may be required to improve antibiotic exposure in patients
treated with beta-lactam antibiotics [16,20].
Source control
Source control frequently is an essential element of the
therapy of severe infections in surgical patients. It refers
to controlling the source of the infection and includes
drainage of pus and inflammatory material as well as de-
bridement of necrotic (infected) tissue. Restoration of
anatomy and function is equally important and often
these components can be combined in one operation.
Source control should be considered in all patients with
severe infections in the SICU. Although the relevance of
source control is not limited to SICU patients, the prob-
ability that this patient group requires source control is
higher due to the high prevalence of abdominal and other
surgical infections [1].
As a rule of thumb, source control measures should not
be delayed except in situations where demarcation of non-
viable tissue and infection is preferable, such as infected
pancreatic necrosis, or in situations where source control
is difficult to obtain, e.g. an infected driveline of a left
ventricular assist device (LVAD). The Surviving Sepsis
Campaign (SSC) guidelines suggest that patients should
be treated within 12 hours [21], but there is no rationale
to defer the intervention unless patient’s physiology is se-
verely impaired and associated with an unacceptable risk
of complications during the source control procedure
such as coagulopathy or life-threatening metabolic disor-
ders. Comparable to the effect of postponing initiation of
antibiotic therapy in case of hypotension, there seems to
be a linear increase in mortality when source control is de-
layed [22]. Timing of source control is often debated and
should be guided by the severity of illness (or rapidity of
deterioration), the (presumed) source of infection and
the physiologic status of the patient (Table 1). Source
control interventions may include surgery but also
other measures can be – initially – adequate such as PCD
or removal of infected tissues or devices.
Therefore it is crucial that institutions that care for these
severely ill patients should have 24/7 access to all diagnos-
tic imaging techniques as well as interventional radiology
and surgery. Although practical issues such as operation
theatre availability and the lack of expertise are often men-
tioned as reasons why source control is delayed, there is
no scientific evidence that delaying source control is safe,
even under broad-spectrum antibiotic coverage. Moreover,
in the era of increasing MRD infections, administering an-
tibiotics to patients in whom the source is not controlled
could lead to the emergence of antibiotic resistance, or se-
lection of less susceptible microorganisms.
Although once considered a surgical issue, source con-
trol measures are no longer limited to the operating the-
atre. Ultrasound or CT-guided PCD is now an important
tool in the early management of severe infections in crit-
ically ill patients. Its exact role however remains to be
determined, and for many infections a surgical proced-
ure still should be considered the standard of care. PCD
however can be a helpful tool during initial resuscitation
and correction of metabolic disorders, but also for more
difficult to surgically treat infections such as infected
pancreatic necrosis, where PCD has emerged as the pre-
ferred initial therapy and can effectively avoid surgery in
a considerable number of patients [24].
To fully understand the impact of the role of source con-
trol in critical care, more attention to this aspect is urgently
needed in studies reporting on the outcome of infected
patients. Quantifying the residual infection after source
control could be helpful to evaluate the role of certain in-
terventions and to guide antibiotic therapy. To this extent
Table 1 Urgency of source control intervention (after [23])
Level of
urgency
Timing of intervention Context




2 As soon as patient
physiology allows
Limited deferral is acceptable
provided antibiotics are
administered and patient is not
deteriorating e.g. peritonitis
3 As soon as infectious
process has demarcated
Adequate source control is
facilitated and probability of
collateral damage lower e.g.
infected pancreatic necrosis
in a stable patient
Table 2 Source control categorization
Source control-status Description
S0 No residual infection
S1 Residual macroscopic infection,
no ongoing contamination
S2 Residual macroscopic infection
and ongoing contamination
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we suggest using a classification system (Table 2) that al-
lows to better describe the net effect of source control mea-
sures. In analogy with oncological surgery where the R
classification reflects the completeness of the surgical pro-
cedure, the proposed categorization of residual infection re-
flects the effect of the source control intervention, supports
planning of future treatment and correlates with prognosis.
The presence of residual infection refers to the presence of
pus, infected tissue after the source control procedure e.g.
incomplete drained abscess after PCD or residual necrotic
material that cannot be debrided. Ongoing contamination
refers to a source that maintains the infection, e.g. a gastro-
intestinal tract perforation that cannot be transformed into
a fistula and continues to soil the abdominal cavity.
Source control treatment options have been poorly in-
vestigated before they entered clinical practice. PCD for
example has been studied to some extent in severe acute
pancreatitis as part of a step-up minimally invasive ap-
proach as opposed to open surgery but for other indica-
tions no randomized studies have been performed.
Novel interventions should be subjected to rigorous
clinical trials but also treatment strategies that have been
taken for granted require re-evaluation. Van Ruler et al.
compared the often applied planned relaparotomy ap-
proach to a more restrictive on-demand relaparotomy
strategy and found the latter to be superior in terms of
morbidity and cost [25].
As source control in critically ill is becoming increasingly
complex, we advocate the development of multidisciplinary
source control teams where intensivists, infectious disease
specialists, surgeons and interventional radiologists discuss
the need for, the timing of and the preferred methodology
used for source control procedures. Continued multidiscip-
linary evaluation is crucial.
Conclusions
In conclusion, the management of infections in surgical
patients poses specific challenges. Diagnosis is often prob-
lematic and the need for source control adds a level of
complexity to the management of the patient. Also the
need for a multidisciplinary approach can make the deci-
sion making difficult. The lack of data have so far led to
vague recommendations regarding source control, and
clinical studies need to report source control methodology
and efficacy. New concepts such as dedicated source con-
trol teams may further assist in selecting the most appro-
priate treatment strategy and further improve outcome of
severe sepsis patients in the SICU.
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